← Home
© 2024 - 2025 InsightfulValue.com. All rights reserved.
Press Releases
Date | Press release |
---|---|
2025-04-28 16:30:00 | Fractyl Health To Present Compelling Preclinical Data From Its Rejuva® Single-administration Smart Glp-1 Pancreatic Gene Therapy Platform At The American Society Of Gene And Cell Therapy (asgct) 2025 Annual Meeting Burlington, mass., april 28, 2025 (globe newswire) -- fractyl health, inc. (nasdaq: guts) (“the company”), a metabolic therapeutics company focused on pattern-breaking approaches to treat the root causes of obesity and type 2 diabetes (t2d), today announced that it will deliver an oral presentation of compelling preclinical data from its rejuva single-administration smart glp-1 pancreatic gene therapy platform at the american society of gene and cell therapy (asgct) 2025 annual meeting, taking place may 13-17, 2025, in new orleans, louisiana. |
2025-04-25 08:30:00 | Global Partners Declares First-quarter 2025 Cash Distribution Of $0.7450 On Common Units Waltham, mass.--(business wire)--global partners lp (nyse: glp) (“global partners” or the “partnership”) today announced that the board of directors of its general partner, global gp llc, has declared a cash distribution of $0.7450 per unit ($2.98 per unit on an annualized basis) on all of its outstanding common units from january 1, 2025 through march 31, 2025. the distribution will be paid on may 15, 2025 to unitholders of record as of the close of business on may 9, 2025. non-u.s. withholdin. |
2025-04-24 08:30:00 | Global Partners Lp To Host First-quarter 2025 Financial Results Conference Call On May 8, 2025 Waltham, mass.--(business wire)--global partners lp (nyse: glp) (“global partners” or the “partnership”) today announced that it will release its first-quarter 2025 financial results before the market opens on thursday, may 8, 2025. at 10:00 a.m. et, the partnership will conduct a conference call for investors and analysts hosted by eric slifka, president and chief executive officer, gregory b. hanson, chief financial officer, and mark romaine, chief operating officer. the call can be accessed. |
2025-04-23 09:10:00 | Recent Glp-1-industry Developments Highlight The Promise Of Lexaria Bioscience’s Technology Pfizer and eli lilly reporting significant - and opposing - news in the glp-1 industry lexaria’s technology could enhance performance and lower side effects kelowna, bc / access newswire / april 23, 2025 / lexaria bioscience corp. (nasdaq:lexx)(nasdaq:lexxw) (the \"company\" or \"lexaria\"), a global innovator in drug delivery platforms, provides the following glucagon-like peptide-1 (\"glp-1\") strategic update following important industry developments reported both by pfizer® inc. and by eli lilly and company®. nearly all of the world’s top pharmaceutical companies are racing to develop new oral glp-1 drugs, including: amgen®, astrazenca, eli lilly, merck®, novo nordisk®, pfizer®, and roche®. |
2025-04-22 19:30:00 | Ascletis Announces Positive Topline Results Of U.s. Phase Ib Multiple Ascending Dose Study Of Small Molecule Oral Glp-1r Agonist Asc30 And Submission Of 13-week Phase Iia Study Protocol To Fda - asc30 oral once-daily tablet demonstrated a 6.5% placebo-adjusted mean body weight reduction from baseline after four-week treatment using weekly doses with titrations of 2 mg, 10 mg, 20 mg , and 40 mg doses. - asc30 oral once-daily tablet also demonstrated a 4.5% placebo-adjusted mean body weight reduction from baseline after four-week treatment using weekly doses with titrations of 2 mg, 5 mg, 10 mg, and 20 mg doses. |
2025-04-22 08:31:00 |
|
2025-04-21 09:51:00 |
|
2025-04-17 06:45:00 |
|
2025-04-16 07:00:00 |
|
2025-04-15 07:01:00 |
|
2025-04-14 08:30:00 |
|
2025-04-03 09:10:00 |
|
2025-04-02 09:05:00 |
|
2025-04-01 08:00:00 |
|
2025-04-01 07:00:00 |
|

📰 Browse additional press releases for Global Partners!
Sign up for free or log in
Have you heard about our short Daily Video Newsletter?
Find out more